|New PhRMA Report Shows More Than 160 Medicines in Development for Diabetes and Related Conditions|
|By: PR Newswire Association LLC. - 24 Apr 2019||Back to overview list
WASHINGTON, April 24, 2019 /PRNewswire/ -- Diabetes represents a significant public health issue in the United States. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5 million new cases diagnosed annually, and projections suggest the number of those impacted by the disease will continue to grow.
Diabetes treatment has improved dramatically over the years, with the availability of a range of insulin therapies more closely resembling insulin released naturally in the body as well as other antidiabetic medicines that help patients more effectively manage their condition. The options available today help meet a wide range of unmet needs, providing patients with the tools necessary to stay adherent and healthy—saving costs throughout the health care system. Yet even with these advances, diabetes remains a complex disease to successfully manage and treat.
A new report released today reveals tremendous promise in the diabetes pipeline with 167 innovative new treatments in development for type 1 and type 2 diabetes and related conditions.
As PhRMA president and CEO Stephen J. Ubl highlights in the report, "Researchers and scientists are working on cutting-edge treatments that will make managing diabetes easier, and we are fighting for ways to make these innovations more affordable for patients."
The 167 innovative medicines in development for type 1 and type 2 diabetes and related conditions include:
The 167 medicines in development for diabetes and related conditions represent a heightened understanding of the unique circumstances of each patient and help pave the way for a more promising future for disease treatment.
Despite continuous advances in diabetes treatments, too many patients struggle to afford their insulin and other medicines at the pharmacy counter. Even though prices for insulin after discounts and rebates have fallen in recent years, these negotiated savings are often not shared with patients, resulting in patients with diabetes paying higher out-of-pocket costs for their insulin than their insurer. The biopharmaceutical industry is committed to improving patient access and affordability for medicines, and ensuring treatments meet the needs of all diabetes patients.
For more information on the facts of diabetes, visit PhRMA.org/Diabetes.
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-phrma-report-shows-more-than-160-medicines-in-development-for-diabetes-and-related-conditions-300836658.html
SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)
Copyright 2019 PR Newswire Association LLC.
|Back to overview list|